Summary Aegerion Pharmaceuticals Inc (Aegerion) is a pharmaceutical company that develops therapies for patients with debilitating often fatal and rare diseases. The company provides therapeutics to treat severe inherited lipid disorders. Its therapeutic focus comprise homozygous familial hypercholesterolemia (HoFH), the most severe form of familial hypercholesterolemia. Aegerion offers microsomal triglyceride transfer protein inhibitors, leptin analog replacement therapy and products that reduce low-density lipoprotein cholesterol, total cholesterol, apolipoprotein B and non-high-density lipoprotein cholesterol. Its are used in low-fat diet and other lipid-lowering treatments and in the treatment of complications of leptin deficiency. The company distributes its products across the US. Aegerion is headquartered in Cambridge, Massachusetts, the US. Aegerion Pharmaceuticals Inc (AEGR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile. provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the... Research Beam Model: Research Beam Product ID: 1747474 250 USD New
Aegerion Pharmaceuticals Inc (AEGR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile.
 
 

Aegerion Pharmaceuticals Inc (AEGR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile.

  • Category : Pharmaceuticals
  • Published On : July   2017
  • Pages : 36
  • Publisher : GlobalData
 
 
 
Summary

Aegerion Pharmaceuticals Inc (Aegerion) is a pharmaceutical company that develops therapies for patients with debilitating often fatal and rare diseases. The company provides therapeutics to treat severe inherited lipid disorders. Its therapeutic focus comprise homozygous familial hypercholesterolemia (HoFH), the most severe form of familial hypercholesterolemia. Aegerion offers microsomal triglyceride transfer protein inhibitors, leptin analog replacement therapy and products that reduce low-density lipoprotein cholesterol, total cholesterol, apolipoprotein B and non-high-density lipoprotein cholesterol. Its are used in low-fat diet and other lipid-lowering treatments and in the treatment of complications of leptin deficiency. The company distributes its products across the US. Aegerion is headquartered in Cambridge, Massachusetts, the US.

Aegerion Pharmaceuticals Inc (AEGR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile. provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Aegerion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Aegerion Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Aegerion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Aegerion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Aegerion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Aegerion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Aegerion Pharma Acquires Rights to Myalept from Amylin Pharma 10
Licensing Agreements 11
Aegerion Pharma Enters into Licensing Agreement with Amryt Pharma 11
Equity Offering 12
Aegerion Pharma Completes Public Offering Of Common Stock For US$83 Million 12
Aegerion Pharma Completes Public Offering Of Common Stock For US$56 Million 13
Aegerion Pharma Completes Public Offering Of US$53 Million 15
Aegerion Pharma Completes IPO Of US$54.6Million 16
Debt Offering 18
Aegerion Pharma Raises USD325 Million in Private Placement of Notes Due 2019 18
Acquisition 19
QLT Acquires Aegerion Pharma 19
Aegerion Pharmaceuticals Inc - Key Competitors 21
Key Employees 22
Locations And Subsidiaries 23
Head Office 23
Recent Developments 24
Financial Announcements 24
Nov 03, 2016: Aegerion Pharmaceuticals Announces Third Quarter 2016 Financial Results 24
Aug 09, 2016: Aegerion Pharmaceuticals Announces Second Quarter 2016 Financial Results 26
May 16, 2016: Aegerion Pharmaceuticals Announces First Quarter 2016 Financial Results 28
Feb 25, 2016: Aegerion Pharmaceuticals Announces Fourth Quarter and Full Year 2015 Financial Results 30
Jan 11, 2016: Aegerion Pharmaceuticals Reports Preliminary 2015 Net Product Sales and Other Business Updates 33
Corporate Communications 34
Jan 07, 2016: Aegerion Pharmaceuticals Appoints Mary Szela as Chief Executive Officer 34
Other Significant Developments 35
Sep 19, 2016: Veristat Strengthens Its Long-Standing Relationship with Aegerion Pharmaceuticals by Establishing a Preferred Provider Agreement 35
Appendix 36
Methodology 36
About GlobalData 36
Contact Us 36
Disclaimer 36

List of Tables
Aegerion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2015 1
Aegerion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Aegerion Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Aegerion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Aegerion Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Aegerion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Aegerion Pharma Acquires Rights to Myalept from Amylin Pharma 10
Aegerion Pharma Enters into Licensing Agreement with Amryt Pharma 11
Aegerion Pharma Completes Public Offering Of Common Stock For US$83 Million 12
Aegerion Pharma Completes Public Offering Of Common Stock For US$56 Million 13
Aegerion Pharma Completes Public Offering Of US$53 Million 15
Aegerion Pharma Completes IPO Of US$54.6Million 16
Aegerion Pharma Raises USD325 Million in Private Placement of Notes Due 2019 18
QLT Acquires Aegerion Pharma 19
Aegerion Pharmaceuticals Inc, Key Competitors 21
Aegerion Pharmaceuticals Inc, Key Employees 22
List of Figures
Aegerion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
Aegerion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
Aegerion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
Aegerion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
Aegerion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Aegerion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6
Aegerion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Aegerion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
PURCHASE OPTIONS
 
 
 

How can we help you?

Contact us at the Consulting WP office nearest to you or submit a business inquiry online.


  Contact
 

Subscribe to Our Newsletter